We reached out to our colleague John Farley, Recruitment & Community Relations Manager at the Center on Substance Use and Health (CSUH) and asked him to share information about the Center’s current projects and recruitment activities.
Frank: John, can you first tell us a little bit about the Center on Substance Use and Health and its mission?
John: Of course. The mission of the Center on Substance Use and Health is to create better health outcomes for all people who use substances through studying and supporting pharmacologic, behavioral, and system interventions addressing substance use and related health outcomes.
CSUH is housed in the San Francisco Department of Public Health and was originally known as the Research Unit of the HIV-Prevention Section, and run by now-Director Dr Grant Colfax.
In 2012, Dr. Phillip Coffin took to the helm and the portfolio expanded to include additional health issues affecting people who use substances, including several substance use disorders, hepatitis C virus, and drug overdose. CSUH has further expanded to include studies related to opioid therapy for chronic pain and supporting primary care providers. Investigators include Drs. Coffin, Santos, and McMahan as well as trainees and visiting scholars. Our work honors San Francisco values and is founded on the core elements of harm reduction. We proudly serve all sexual orientations, races/ethnicities, and gender identities.
Frank: For more information on the Center on Substance Use and Health please take a few moments to visit their website at www.csuhsf.org. The website offers more details on active studies and study results, community outreach and resources, as well as its own blog.
John: Currently the Center on Substance Use and Health has several studies in active enrollment that providers may find useful to be aware of including:
PRIME: A two-arm trial evaluating a strategy to support PrEP adherence in men who have sex with men and trans females who use methamphetamine and inject substances. All participants will receive open label Descovy (PrEP) and counseling during the study. Participants will be randomized 1:1 to receive video directly observed therapy (using a mobile app to submit videos of them taking their PrEP). Eligible participants are compensated up to $619 over the course of the study. For more information, or to see if you are eligible, please call 628.217.6319, email: firstname.lastname@example.org or visit our website at: www.sfprime.org
M3.0: A Phase 1 drug-drug interaction (safety) trial of mirtazapine for methamphetamine use disorder. Participation includes a 14-day hospital stay. The purpose is to determine if mirtazapine alters the cardiovascular response and pharmacokinetics to IV methamphetamine and to evaluate these in the presence of methadone use (12 participants meth/no opioid use, 12 meth/methadone maintenance). This study has two sites, San Francisco and Los Angeles. Eligible participants are compensated up to $2,430. For more information or questions about eligibility please call 628.217.6319, email: email@example.com or visit our website at www.m3study.org
Harness: A study testing whether an herbal supplement (Kudzu) taken on an as-needed basis can help to reduce someone’s alcohol use. Eligible participants are compensated between $10-$50 for a total of $444 over the course of the study. To see if you are eligible, please call us at 628.217.6333. Email address: firstname.lastname@example.org or visit our website at www.sfharness.org
Reboot 2.0: Is a study for people who use illicit opioids and have been a recipient of naloxone. We are testing a counseling intervention to see if it could reduce someone’s overdose risk. Eligible participants are compensated between $10-$50 for a total of $392 over the course of the study. For more information or questions about eligibility, please call us at 628.217.6325. Email: email@example.com Website: www.reboot2.org
For more information or to contact Center on Substance Use and Health